Sign Up
Stories
Biopharma Innovations in Obesity and Muscle Preservation
Share
Biopharma Innovations and FDA Decisions
Diabetes Drug Markets' Growth and Domina...
Eli Lilly Acquires Versanis Bio
89bio to Present pegozafermin for NASH a...
ANJESO Drug Insight and Market Forecast
Amgen's Obesity Prospects and Q4 Results...
Overview
API
Elevai Biosciences and Veru Inc. showcase advancements in obesity and muscle preservation treatments, respectively, utilizing GLP-1 receptor agonists. Elevai plans clinical trials for EL-22 to address obesity while preserving muscle mass, while Veru focuses on muscle preservation and innovative medicines, including enobosarm, presented at the GLP-1 Based Therapeutics Summit.
Ask a question
How might the progress in developing muscle-preserving treatments impact the landscape of obesity therapies?
In what ways could the presentation at the GLP-1 Based Therapeutics Summit influence future research and development in the biopharmaceutical industry?
What potential synergies or differences exist between Elevai's EL-22 and Veru's enobosarm in treating muscle-related conditions?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage